Janus Henderson Group PLC's Form 4 filing
Oruka Therapeutics, Inc.ORKA · filed Aug 20, 2024
- Accession no.
- 0001437749-24-027344
- Filed
- Aug 20, 2024, 2:23 PM ET
- Trade date
- Aug 16, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $17.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Janus Henderson Group PLCCIK 0001274173 | 10% Owner |
| Janus Henderson Biotech Innovation Master Fund LtdCIK 0002030299 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2024 | Common Stock | PPurchaseAcquired | +5,390 | $2.93 | +$15,792.7 | 2,116,785 | Indirect | |
| Aug 16, 2024 | Common Stock | PPurchaseAcquired | +428 | $2.98 | +$1,274.07 | 2,117,213 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.